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Abstract   
Non motor symptoms (NMS) represent a significant burden in Parkinson’s disease (PD) with 
numerous studies highlighting the importance of NMS both in “pre-motor” phase of PD as 
well as throughout the disease course. In part this has led the international Parkinson and 
Movement Disorder Society (IPMDS) task force to attempt a re-definition of PD 
incorporating NMS and not base the diagnosis solely on motor symptoms. While motor 
subtypes within PD have been recognized and researched, recent, clinical and neurobiological 
research suggests the existence of discrete non-motor subtypes in PD, particularly in 
untreated (drug naïve) and early PD patients. Several independent observers have reported 
specific “clusters of NMS dominant PD” using a data driven approach in early and untreated 
PD patients while others have reported on the burden of NMS in untreated PD and specific 
NMS dominant phenotypes in untreated or treated PD using observational case series based 
data. In this review we report on specific NMS dominant phenotypes of PD as described in 
the literature using clinical observational studies and address pathophysiological concepts. A 
proposal for several NMS subtypes are reported combining clinical reports with, where 
possible, evidence base supporting probable biomarkers. 
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Introduction 
Why non motor subtypes? 
Motor symptoms of Parkinson’s disease (PD) such as tremor, bradykinesia and rigidity are 
the hallmark based on which diagnosis and treatment are started and are now known to be 
preceded by the “pre-motor” phase of PD largely dominated by a range of different non 
motor symptoms (NMS) [1-3] 
Virtually every PD patient has NMS, which are now widely recognized as an important 
unmet need in PD [3] and a major determinant of health related quality of life (QoL) of 
patients with PD and their carers [4]. In a survey by Parkinson’s UK, patients listed NMS 
such as pain, sleep disorders and anxiety ahead of motor problems in clinical importance, and 
two further studies have outlined the key impact of NMS as declared by patients themselves 
[3-5]. 
Despite this importance, little has been done to establish NMS clinical phenotypes in the 
context of the multi-morbid PD patient even though several workers have reported clinical 
phenotypes driven by specific NMS such as pain, cognitive problems, apathy and sleep 
dysfunction. Additionally, cluster analysis from several large early PD and untreated cohorts 
have all suggested specific NMS dominant or only NMS driven clustering [12-14]. This 
review aims to highlight these phenotypic variants that have been described within the rubric 
of Parkinson’s disease. 
 
Pathophysiological basis of non-motor subtypes in Parkinson’s disease (PD)  
NMS based subtyping of PD is plausible from the clinical point of view that in some PD 
patients, but not all, specific NMS are predominantly expressed, while in others NMS may 
not be evident or are less relevant. The clinical expression of a range of NMS highlight the 
fact that the phenotype of PD results from varying rates of Lewy body deposition and 
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neurodegeneration in PD and represents the effects of widespread brain and peripheral Lewy 
body pathology instead of a single neural structure affected or the loss of the monoamine 
neurotransmitter such as dopamine (DA) [3,5]. This convergence of deficits in multiple 
transmitter systems and pathways, including the cholinergic, noradrenergic, and serotonergic 
systems, may all be associated with clinical expression of NMS. In addition, glial pathology, 
neuroimmune responses, and proinflammatory cytokines may also play a key pathogenic role 
adding to the heterogeneity of PD [5-6]. Furthermore, non-dopaminergic areas in the 
brainstem may be affected and involved ahead of dopaminergic involvement as recently 
reviewed by Todorova et al [3, 5-7.] Jellinger has suggested that neuropathological spread of 
the neurodegenerative process may be initiated via the olfactory bulb and thereafter through 
the limbic or brainstem areas while spread via the enteric nervous system via the nervus 
vagus has also been suggested [5-8]. A limbic or brainstem dominant pathophysiological 
process as proposed by Jellinger [5]. Halliday et al [7] or Beach et al [9] is the basis of our 
proposal of limbic or brainstem process dominant NMS subtypes as shown in Figure 1.  All 
of these processes would lead to dominant expression of NMS over motor symptoms as also 
underpinned by the Braak hypothesis of α-synuclein accumulation starting in the lower 
brainstem and the olfactory bundle well before there is significant involvement of substantia 
nigra.  
NMS subtyping is thus based on the evidence that early and substantial neuronal loss occurs 
in many non-dopaminergic nuclei in the limbic and brainstem areas, either before or 
concomitantly with involvement of dopaminergic projections [5, 9-10]. The dorsal motor 
nucleus of the vagus (DMV) is a key area for control of autonomic signaling responsible for 
symptoms such as constipation. Neuronal loss in the dorsal motor nucleus of vagus could be 
as profound as that in the substantia nigra (SN), and large (43-57% loss) cholinergic and 
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substance P expressing neurons are preferentially lost while tyrosine hydroxylase neurons 
may be relatively spared in PD [5, 10].  
A further contributor in the pathophysiology of non motor subtypes within PD is the age of 
onset of PD. Preferential Lewy body deposition in in the brainstem in young onset PD versus 
a cortical dominant pathology in late onset PD has been described, the latter being associated 
with Alzheimer’s disease type pathology [11]. 
It is likely therefore, in these subjects patterns of NMS, dependent on relevant 
neuropathological involvement of non-dopaminergic areas, will underpin the clinical 
expression of specific NMS such as sleep problems, apathy, pain, depression/anxiety, ahead 
of and dominating the typical motor deficit of PD.  
 
Evidence from studies in untreated PD 
Untreated PD patients represent a suitable model to study the expression of NMS in 
comparison to motor symptoms. Erro et al. have conducted a cluster analysis coupled with 
validated cognitive, motor and non-motor assessments in a untreated PD cohort and found 4 
discrete clusters within the cohort termed benign pure motor, benign mixed motor-non-motor, 
non-motor dominant and  motor dominant [12].  The non-motor dominant cluster reported 
higher urinary dysfuction and a rapid progression rate compared to the benign mixed motor, 
non-motor cluster.  
In the recently reported ONSET-PD study, the authors highlighted specific non motor 
clusters of PD ranging from cognitive and mood clusters to sensory, RBD dominant and 
autonomic dysfunction related cluster further supporting our attempt of NM subtying of PD 
[13]. Studies have also identified specific clinical phenotypes in untreated PD underpinned by 
NMS such as sleep dysfunction, cognitive and neurosychiatric disturbances (depression, 
apathy), fatigue, dysautonomia, pain and olfaction recently reviewed by Zis et al [14]. These 
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observations fit well with the neuropathological studies, which have suggested a differential 
rate of neuronal degeneration and Lewy body deposition in the non-dopaminergic brainstem 
and limbic areas in PD, with consequent expression of a variety of related NMS.  
 
The Literature descriptions of specific NMS dominant subtypes of PD: 
A proposal of at least six different NMS dominant clinical phenotypes within PD mainly in 
early and untreated phase has been proposed based on clinical observation and in this review 
we discuss the patterns that have been reported and published so far [15]. 
 
Park Cognitive  
Clinically the Park Cognitve subtype predominantly presents with cognitive impairment even 
at an early stage.  
Neuropathologically, this subgroup may represent the late onset pattern of Lewy body 
deposition [7]. The patients are likely to present with mild cognitive impairment (MCI), 
which may progress to frank dementia (Figure 1). The condition overlaps clinically with 
dementia with Lewy bodies (particularly when there is fluctuating cognitive state however, 
Park cognitive shows sustained levodopa responsiveness) and Alzheimer’s disease. The use 
of thioflavin ligand based positron emission tomography (PET) scans, amyloid scans, 
cholinergic imaging or cortical thinning (functional MRI) may help to  further refine the 
clinical classification [16]. 
Early dementia – probably reflecting a high cortical Lewy body load, occurs but importantly 
the patients retain levodopa responsiveness in part. Clinical studies by Williams-Grey et al. 
suggest that in this cohort (Park Cognitive) impaired semantic fluency (less than 20 words in 
90 sec) and inability to copy an intersecting pentagons figure are predictive of dementia [17].  
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Clinical differences between amnestic and non-amnestic subtypes within the PD-MCI have 
been reported and Microtubule-associated protein tau (MAPT) H1/H1 genotype may be a 
molecular biomarker [17-18] (Table 1a). 
 
Park Apathy 
Clinically the Park Apathy subtype score high on apathy scales, and specific apathy dominant 
phenotype in untreated PD excluding the possibility of dopamine agonist withdrawal 
syndrome as a confounder [18] (Table 1b). There are also high rates of cognitive impairment 
as well as anhedonia in these cases. Current perception suggests apathy in PD may be a 
dopamine responsive NMS. Clinically, some patient might present with severe apathy but 
mild Parkinsonism and need treatment in spite of their mild motor impairment. 
 
Park Depression/Anxiety 
Clinically the Park depression/anxiery phenotype might occur in both late and early onset PD 
with both depression and anxiety and it is important to consider these symptom in the context 
with motor fluctuations. This description is based on the clinical analysis of cases as reported 
in the Prospective Study of Mood States in Parkinson’s Disease (PROMS-PD) study [19-20]. 
Brainstem as well as the limbic involvement could be responsible (Figure 1). The clinical 
protocol for the PROMS-PD study specifically addressed fluctuation related changes in 
depression and anxiety states to account for non motor fluctuations as well as exclusion of 
confounders such as generalized anxiety states or comorbid illnesses. 
Three different subtypes namely anxious depressed, depressed, anxious as well as 
psychologically healthy subtype have been described (Table 1c) and there is a correlation 
with cognitive impairment and an overlap with the Park Cognitive phenotype (Figure 1).  
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Reduced catecholaminergic (11C-RTI-32) binding has been reported in depressed versus non-
depressed PD patients and reduced binding in ventral striatum, medial thalamus, and locus 
ceruleus was associated with severity of anxiety (but not depressive) symptoms [21]. 
 
Park Sleep 
Clinically the phenotype could be divided into two subtypes (Figure 1). The first type is 
characterized by excessive daytime sleepiness (EDS) (high scores on the Epworth sleepiness 
scale (ESS)) and clinically complaints of severe somnolence. Some may have narcolepsy 
without cataplexy and may be particularly susceptible to the sedating effects of dopamine 3 
receptor agonists.  This subtype is at particular risk of sudden onset of sleep during initiation 
and up-titration of dopamine agonist therapy. Abnormalities in the central orexin pathway 
and loss of orexin containing cells in hypothalamus may underpin this subtype.  
The second type presents with rapid eye movement (REM) behaviour disorder (RBD), a sleep 
disorder subtype characterized by motor enactment of violent intrusive and aggressive 
dreams during REM sleep (Table 1d). RBD is typically manifested as a pre-motor 
phenomenon and can be linked to synucleinopathies . 
The EDS specific phenotype has been independently described by various authors [22].  
A central brainstem generator in the midbrain area centered around the pedunculopontine 
area and sublaterodorsal nucleus has been suggested in RBD and supported by imaging 
studies showing reduced factional anisotropy as well as reduced midbrain tegmental 18F-dopa 
uptake [23]. Imaging studies have also identified and supported the concept of specific sleep 
subtypes. Recent studies using 11C-labeled 3-amino-4-(2-dimethylaminomethyl-
phenylsulfanyl) benzonitrile (11C-DASB) PET, a serotonin transporter marker, have 
suggested specific deficits in serotonergic neurotransmission in the dorsal and ventral raphe 
nucleus (arousal areas) in patients with EDS but not in controls or those without EDS [24]. 
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Histopathological studies suggest a deficiency of orexin containing neurons in somnolent PD 
cases but not controls, and this has also been suggested by low orexin levels in brain 
ventricular fluid samples, although data from lumbar puncture samples are contradictory [3].   
Park Pain 
Clinically the Park Pain subtype express a range of different pain syndromes which dominate 
the clinical picture; this possibly represents the phenotype previously described as “painful 
Parkinson’s disease” by Quinn et al in 1986 [27]. 
The Park Pain subtype has a higher risk to develop disproportionate pain during the 
progression of PD compared to the motor severity of disease. Several variants of pain such as  
nociceptive and neuropathic, central, peripheral, radicular and fluctuation-related, are 
described and an unexplained lower limb pain syndrome is the only subtype that has been 
well described so far  (Table 1e) [28]. Refinement of the population studied have been aided 
by a new pain classification now published as a validated pain scale for PD which have 
allowed exclusion of secondary pain in PD as far as possible. 
 
Park Fatigue 
There is now growing evidence that fatigue indeed is an independent NMS separate from 
apathy or sleep dysfunction. Several patient report based publications have also identified 
fatigue as a major patient reported problem where there is no depression or somnolence.  
Clinically the Park Fatigue subtype suffers from severe fatigue, a sense of exhaustion as 
defined and assessed by recommended scales of the international Parkinson and Movement 
Disorder Society (IPMDS) task force. At least two studies have identified fatigue to be a 
major NMS in untreated PD as well as early PD [14, 25]. The distinction between central and 
peripheral fatigue can also overlap, but recent studies suggest that this subtype can be 
independently recognized using specific PET studies showing central limbic serotonergic 
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deficit separate from the raphe serotonergic deficit seen in Park Sleep (EDS) subtype [26]. In 
this study, patients with Park fatigue, who where matched with a healthy control group as 
well as PD patients without fatigue in terms of motor scores, depression scores as well as 
excessive daytime somnolence assessments, showed a specific limbic serotonergic deficit. 
 
 
Park autonomic 
Clinically the Park Autonomic subtype presents with a variety of autonomic dysfunctions 
including sexual dysfunction, constipation to urinary frequency, urgency and nocturia as their 
predominant symptoms. Broadly the phenotypes could be subdivided to: 
 Gastro-intestinal symptoms dominant and   
 Genito-urinary symptoms dominant (dominated by urinary symptoms) (Figure 1).  
 Adrenergic dysfunction dominant (clinically dominated by postural hypotension, 
post-prandial hypotension and also post exercise hypotension) (reviewed in [29]). 
 
Neuropathologically, a dominant noradrenergic deficit is likely to be the key and a recent 
review has highlighted the role of noradrenergic deficit in PD and the need for specific 
noradrenergic treatment [29] These patients are also likely to represent the PD with 
autonomic failure (as opposed to MSA) phenotype and while the clinical picture may be 
dominated by postural hypotension, symptoms secondary to postprandial hypotension such as 
post-meal dizziness and excessive somnolence or post exercise hypotension are also evident. 
[29]. Iodine-131-meta-iodobenzylguanidine (MIBG) cardiac scans can detect cardiac 
sympathetic denervation (equivalent to a non visualization of the heart) even before the onset 
of motor symptoms in PD, while in many other cases loss of cardiac sympathetic innervation 
appears to progress approximately concurrently with the movement disorder or in some 
patients can be a late finding. In terms of NMS, apart from postural hypotension and features 
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of the adrenergic variants, cardiac MIBS abnormalities have also been implicated in fatigue 
related to PD. 
In addition Sharma and colleagues have described a phenotype characterized by a weight loss 
combined with severe olfactory dysfunction and dyskinesia in PD as shown in Table 1f (Park 
weight phenotype)[30]. 
 
The problems of non-motor subtyping 
As PD is a heterogeneous disorder there is considerable possibility that these subtypes will 
overlap and are likely to be present only in a proportion of patients. Comparable with the 
instability of motor subtypes, non-motor subtypes will change throughout the course of 
disease and at the end several types will merge and overlap. As such we accept that the 
classification is a simplification with heterogeneity and overlapping probably existing within 
these proposed major subtypes. 
Selection bias within the samples examined may be considered a problem, however, 
clustering based as well as clinical observational phenotyping based papers have been in 
mostly in untreated or early PD patients and as such with no major selection bias because the 
basic inclusion is a diagnosis of motor PD. For instance Park cognitive or Park pain types 
have been based on symptom expression from a population based PD sample presenting to 
the clinic and not a sample specifically screened and selected for non motor studies. 
NMS subtyping is an important advance in the translation of pathophysiology advances in PD 
to clinical practice and we would like to suggest that NMS subtyping would enrich the design 
of clinical trials and recruitment of patients as well improve the knowledge about the natural 
history of PD, which thus far have only addressed motor symptoms. For instance: 
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1. A Park sleep subtype with a narcoleptic variant may be intolerant to D3 active 
dopamine agonist and vigilance would be required especially when such patients are 
on DA and driving. This could be applied to patient selection for related clinical trials. 
2. A Park Fatigue subtype could be an ideal group to attempt a clinical trial of serotonin 
receptor agonist agent rather than selecting a general cohort of PD based on Pavese et 
al study [26] 
3. A Park pain phenotype would be a good candidate for opioid based therapies 
(PANDA study (ClinicalTrials.gov Identifier:NCT01439100) based on opioid versus 
placebo therapy in Parkinson associated pain has started  
As with most clinical observations in PD there is likely to be overlap as indeed between the 
well established motor subtypes; for instance, many akinesia dominant phenotypes may 
develop tremor or postural instability subtype. The success of our proposed NMS subtypes 
can only be validated by natural history studies and while the evidence (pathophysiological as 
well as from a biomarker point of view ) is strong for some NMS subtypes (cognitive, 
adrenergic, sleep) for others such as pain it currently is rather weak. 
 
Conclusion 
NMS subtyping in PD is a new concept and as shown in this paper is clinically relevant and 
possible. The process emphasizes the value of incorporating NMS as an obligatory clinic 
assessment which aims to ensure that NMS are not missed in the clinic currently dominated 
by motor assessment and leads to sub-optimal care. Subtyping of clinically heterogeneous 
conditions is possible and regarded as routine clinical practice in conditions such as multiple 
sclerosis, motor neuron disease, and epilepsy, and this has now led to subtype-directed 
treatment strategies in some of these conditions. We feel, this is also possible, and desirable, 
in a highly clinically heterogeneous condition such as PD and in future, may lead to 
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development of focused NMS outcome based clinical trials in carefully selected patients, a 
key unmet need in PD as well as shed light on NMS based natural history pattern in PD.  
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Brainstem ± Olfactory route 
(Braak et al. Ref 14, Jelllinger. Ref 7, Espay et al. Ref 29) 
 
 
Olfactory route 
(Beech et al. Ref 11) 
 
Cognitive (older age of onset) 
(Halliday et al. Ref 9, Weintraub et al 2015) 
 
 
Figure 1: A proposed concept illustrating the pathophysiological, clinical and possible 
biomarker based concepts underpinning non motor subtypes in PD. The sagittal section 
Adrenergic (postural  
and other 
hypotension) 
 
 
 
Brainstem 
Phenotype 
 
Limbic 
Phenotype 
 
Cortical 
Phenotype 
(late onset) 
Serotonergic 
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diagrams show possible routes of spread of the pathophysiological process in PD as 
published. The cognitive phenotype is underpinned by age of onset. Adrenergic 
(autonomic dominant) and serotonergic (fatigue) represent reports of specific 
neurochemical deficits underlying these subtypes as reported in literature (references 29 
and 26) 
EDS= Excessive daytime sleepiness ; RBD= REM sleep behavior disorder; GIT= Gastro 
intestinal tract; GUT= Genito urinary symptoms; MCI= Mild cognitive impairment.  
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Table 1 Different possible subtypes within Parkinson’s disease as described in literature 
a) Cognitive subtype in Parkinson’s disease [20] 
 Older age (≥ 72 years)                            
 Non-tremor dominant motor phenotype 
 Unified Parkinson’s Disease Rating Scale (UPDRS) score ≥ 25 
 Poor semantic fluency score (<20) 
 Lower pentagon copying score (0<1<2) 
 Microtubule-associated protein tau (MAPT) H1/H1 genotype 
b) Apathy subtype in drug naïve Parkinson’s disease [18] 
 High scores on apathy rating scales 
 Relatively severe motor symptoms  
 Concomitant depression 
 Lower cognitive status 
 Fatigue 
 Anhedonia and response to dopaminergic drugs 
c) Depression/Anxiety subtypes in Parkinson’s disease [19-20]  
1. Anxious depressed subtype  
 Younger age 
 Early age of onset 
 Long disease duration 
 Significant motor disability and higher Unified Parkinson’s Disease Rating Scale 
(UPDRS)  scores 
 Postural instability/falls  subtype 
 Motor fluctuations  
 Significant cognitive impairment 
 Markedly increased levels of anxiety and depression 
2. Depressed subtype  
 Older age 
 Late age of onset 
 Shorter duration of Parkinson’s disease 
 Postural instability gait disturbance (PIGD) subtype 
 Significant motor impairment and disability 
19 
 
 Motor fluctuations 
 High levels of depression  
3. Anxious subtype  
 Younger age 
 Young age of onset 
 Advanced disease with motor fluctuations 
 Postural instability gait disturbance (PIGD) subtype 
 Cognitive impairment 
 High levels of anxiety 
d) REM sleep behavior disorder subtype in Parkinson’s disease [22]  
 Symmetric disease onset 
 Increased periods of freezing  
 Autonomic dysfunction - Prone to higher prevalence and severity of orthostatic 
symptoms 
 Higher rate of depression 
 Visual hallucinations 
 Male gender 
 Older age 
 Non tremor dominant subtype/ akinetic rigid syndrome  
 Increased frequency of falls 
 Depression 
 Higher Hoehn and Yahr motor stage 
 Impairment of colour vision  
e)  Lower limb pain subtype in Parkinson’s disease [27-28] 
 Male>female 
 Across all age groups 
 Moderate to advanced Parkinson’s disease 
 Pain in anterior proximal aspect of lower limb, described as internal pain 
 Lack of effect of physiotherapy 
 Unrelated to non motor fluctuations 
 Responsive to opiates 
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f) Park weight subtype (combined with olfactory dysfunction and dyskinesia) in 
Parkinson’s disease [30] 
1. Phenotype A – More severe loss of olfaction (anosmia) 
 Higher initial body weight                            
 Weight loss with progression of disease 
 Higher risk of dyskinesias 
 More severe neurodegeneration 
 Longer premotor disease duration 
2. Phenotype B – Less loss of olfaction (hyposmia) 
 Lower initial body weight 
 No weight loss/ weight gain with progression of disease 
 Lower risk of dyskinesias 
 Slower neurodegeneration 
 Shorter premotor disease duration 
 
 
